University of Oxford’s genetic therapeutics spinout has secured the crossover funding eight months after a series A round also backed by OSI.
PepGen, a UK-based neuromuscular disorder therapy developer spun out of University of Oxford, has raised $112.5m in crossover financing featuring university venture fund Oxford Sciences Innovation (OSI).
CureDuchenne Ventures, RA Capital Management, Viking Global Investors, Deerfield Management, Qatar Investment Authority, Adage Capital Management, Samsara Biocapital, Laurion Capital Management, Tudor Investment and Gray’s Creek Capital Partners all contributed.
Founded in 2018, PepGen is developing genetic therapies to treat neuromuscular and neurologic diseases using its Enhanced Delivery Oligonucleotide platform, which helps target RNA sequences that trigger the disorders.
RA Capital Management led a $45m series A round in December 2020, investing alongside OSI and CureDuchenne’s CureDuchenne Ventures unit.
OSI had already provided $5.2m in a 2018 seed round for PepGen, which included CureDuchenne and the Medical Research Council, a funding agency operated by public body United Kingdom Research and Innovation.
